MMF GI Intolerance Myfortic Switch — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

EasyGlomerulonephritisMMF GI Intolerance Myfortic SwitchESENeph

A 40-year-old woman with SLE and Class IV lupus nephritis on induction Mycophenolate develops persistent vomiting and diarrhoea limiting her oral intake. Her Mycophenolate dose is subtherapeutic due to GI intolerance. What alternative formulation or drug might help?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Change mycophenolate formulation

Mycophenolate mofetil (MMF) causes dose-dependent GI side effects (nausea, vomiting, diarrhoea) in 20-40% of patients. Enteric-coated Mycophenolate sodium (EC-MPS, Myfortic) releases the active drug in the small intestine rather than the stomach, potentially improving upper GI tolerability. KDIGO 2024 LN guideline acknowledges that GI intolerance may limit MMF dose. If switching formulations does not resolve GI intolerance, alternatives include Azathioprine (less potent but better tolerated), IV Cyclophosphamide (pulse protocol), or addition of Belimumab to allow lower MMF doses. The competing options do not fit the renal phenotype, temporal relationship, treatment threshold or safety constraint described. Management still requires confirmation of current medicines, renal trajectory and relevant contraindications, followed by timely biochemical and clinical reassessment. Escalate urgently if life-threatening electrolyte disturbance, respiratory compromise, shock, neurological deterioration or a dialysis indication develops.

Reference: KDIGO 2024 – Lupus Nephritis; BNF – Mycophenolate Formulations: https://kdigo.org/guidelines/gd/